Agreement - August 22, 2019
Sobi sells Priority Review Voucher to AstraZeneca
Swedish Orphan Biovitrum has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 million. A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target […]
Agreement - August 22, 2019
Alligator signs agreement with Biotheus
Alligator Bioscience has announced that a license agreement has been reached with Biotheus, a privately held Chinese company based in Zhuhai, Guangdong, China. Under the license agreement, Alligator has granted Biotheus rights in Greater China (including Republic of China, Hongkong, Taiwan and Macau) to an antibody from ALLIGATOR-GOLD for the creation of up to three […]
Agreement - August 13, 2019
Calliditas enters in-license agreement
Calliditas Therapeutics has exclusively in-licensed Budenofalk 3mg oral capsule for the US market from the German pharmaceutical company Dr. Falk Pharma. The agreement covers all indications for the US market, excluding orphan indications outside of liver targets. Initially, Calliditas will leverage Dr. Falk’s clinical trial data and expertise in liver indications, such as autoimmune hepatitis […]
Agreement - July 1, 2019
Photocure enters global licensing deal
The company has entered into a License Agreement providing Asieris Meditech with a world-wide license to develop and commercialize Cevira for the treatment of HPV induced cervical precancerous lesions. Asieris plans to launch a global clinical development program with an initial focus on the China market based on Photocure’s Phase 2b data and the Phase […]
Agreement - June 10, 2019
Calliditas Therapeutics in agreement with Everest Medicines
The two companies have entered into a license agreement to develop and commercialize Calliditas’ leading drug candidate Nefecon in Greater China and Singapore for the chronic autoimmune kidney disease IgA Nephropathy (IgAN). Under the terms of the agreement, Calliditas will receive an initial upfront payment of 15M USD at signing of the agreement, as well […]
Agreement - June 4, 2019
Xbrane enters term-sheet with STADA
The company has entered a non-binding term-sheet with STADA Arzneimittel for cooperation regarding sales and marketing of Spherotide for Europe, and furthermore, the company updates on its plans to take the product into a phase III study in endometriosis patients. Non-binding term-sheet with STADA The company´s non-binding term-sheet with STADA consists of an agreement to […]
